Investigating lymphatic signaling in scleroderma fibrosis
Official title: Lymphatic ERG signaling in scleroderma fibrosis
Funded at Boston University Medical Campus · NIH-11112303 · Data updated 2026-11-12
This study is looking at how certain signals in the lymphatic system might affect people with scleroderma, with the goal of finding new ways to improve treatments for this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 7, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $537,014 |
| NIH project number | 5R01AR080950-04 |
| Project ID | NIH-11112303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with scleroderma who are experiencing symptoms related to vascular impairment.
✕Less likely to help
Patients without a diagnosis of scleroderma or those with unrelated vascular conditions may not benefit from this research.
What this research studies
This research focuses on understanding the role of lymphatic signaling in scleroderma, a condition characterized by autoimmune responses and fibrosis affecting multiple organs. The study aims to explore the molecular mechanisms behind the impairment of both blood and lymphatic systems in patients with scleroderma. By analyzing gene expression and signaling pathways, researchers hope to identify new therapeutic targets that could improve treatment options for this condition. The approach includes examining the role of specific transcription factors that may influence lymphatic regeneration and fibrosis.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve healing and reduce fibrosis in patients with scleroderma.
How similar studies have gone: While the specific focus on lymphatic signaling in scleroderma is relatively novel, there is growing evidence supporting the importance of vascular mechanisms in autoimmune diseases.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Trojanowska, Maria — Boston University Medical Campus
- Study coordinator: Trojanowska, Maria
Related research
Other NIH-funded projects on the same topics.
-
Lymphatic ERG signaling and fibrosis in scleroderma
This grant explores how a key gene pathway involved in lymphatic vessels may contribute to fibrosis in scleroderma, with the goal of finding new targets to improve vascular health and tissue healing.
-
New mouse and human lung models to study how T cells drive scleroderma-related lung fibrosis
Aims to understand how specific T cell types contribute to lung scarring in scleroderma by using advanced mouse and human lung models.
-
New treatment for lung fibrosis related to scleroderma
This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.
-
Investigating the role of a specific protein in lung fibrosis related to scleroderma
This study is looking at how a protein called BHLHB2 affects lung scarring in people with scleroderma, hoping to find new ways to help treat lung problems caused by this condition.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.